Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy ..........821
Précis: Multiregion sequencing of esophageal adenocarcinomas pre- and post-neoadjuvant chemotherapy reveals intratumor heterogeneity, a shift in mutation spectra, and ubiquitous amplification of targetable oncogenes that persist post therapy.
See commentary, p. 796

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment ..........832
Précis: Dual HER2 targeted therapy causes regression of patient-derived xenografts of colorectal cancer with HER2 activating mutations.
See commentary, p. 799

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping ..........842
Précis: Patients who have been identified by prospective screening for MET exon 14 splice site mutations would benefit from MET inhibitor treatment.
See commentary, p. 802
See article, p. 850
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors .......... 850

Précis: Integrative analysis identified three major clusters of KRAS-mutant lung adenocarcinoma characterized by co-occurring genetic events in STK11/LKB1, TP53, or CDKN2A/B and divergent biologic and therapeutic profiles.

A Large Multiethnic Genome-Wide Association Study of Prostate Cancer Identifies Novel Risk Variants and Substantial Ethnic Differences ........ 878

Précis: GWAS analysis of a large, ethnically diverse prostate cancer population identified previously unreported risk variants and replicated known risk variants.

---

For more information please visit http://www.aacrjournals.org
CANCER DISCOVERY

5 (8)


Updated version
Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/5/8

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.